BDTX Stock: Black Diamond Therapeutics, Inc. Stock Price, Analysis & Insights
Get live bdtx stock price $2.63, comprehensive Black Diamond Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time bdtx stock data and investment insights.
Loading chart...
Company Overview
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Mark A. Velleca
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 24
Contact Information
- Address
- One Main Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 7.1)
✓ Higher growth potential with elevated volatility (Beta: 3.34)
Business Model & Strategy
Black Diamond Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Mark A. Velleca, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Black Diamond Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 149.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Black Diamond Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Black Diamond Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Black Diamond Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Black Diamond Therapeutics, Inc.
- ⚠Investors should consider how Black Diamond Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
149.56M
P/E Ratio
7.09
Beta
3.34
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 149.56M market capitalization
- Trading Volume: 7.98M shares traded today
- Price Range: 52-week range of $1.20 - $4.94
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. (BDTX) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 149.56M, the company represents a significant player in its market. The stock is currently trading at $2.63 with a negativedaily change of 23.91%.
The company's 24 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 7.09, beta of 3.34, and 52-week price range from $1.20 to $4.94when evaluating investment opportunities.
Why Invest in Black Diamond Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Mark A. Velleca
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.